Rasonque EMA Recommendation: Promising Survival Gains

The Rasonque EMA recommendation is a significant step for people with metastatic pancreatic cancer whose disease has worsened after earlier treatment. On 15 October 2026, Revolution Medicines announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) adopted a positive opinion recommending marketing authorisation for Rasonque (daraxonrasib), a once-daily oral RAS inhibitor. The proposed use is as monotherapy in adults with metastatic pancreatic adenocarcinoma who have received at least one prior systemic therapy. It is a recommendation, not an approval: the European Commission makes the final decision.

Below we explain what was recommended, which survival figures to trust, what the side effects are, and what has to happen before patients in Europe can be prescribed the drug.

Rasonque EMA recommendation: key takeaways

• The CHMP recommended marketing authorisation. The European Commission has not yet decided, and no date was given.
• Proposed use: adults with metastatic pancreatic adenocarcinoma after at least one prior systemic therapy.
• In the Phase 3 RASolute 302 trial, median overall survival was 13.2 months with Rasonque versus 6.7 months with chemotherapy in the main analysis.
• A later ad hoc analysis gave 12.4 months versus 6.7 months. Median progression-free survival was 7.2 versus 3.6 months.
• Side effects were frequent, mainly rash, diarrhoea and mouth sores. The drug is not a cure.

What the Rasonque EMA recommendation covers

The opinion covers Rasonque as a single agent, taken as a tablet once a day, for adults with metastatic pancreatic adenocarcinoma who have already had at least one systemic treatment. The company says the review ran under the EMA’s Cancer Medicines Pathfinder project, an expedited, phased review for medicines that address significant unmet needs, and that the drug holds orphan designation for pancreatic cancer. If the European Commission follows the committee, authorisation would apply across the EU and in Iceland, Norway and Liechtenstein, but not in the UK or Switzerland, which have separate processes. Decisions are recorded in the Union Register of medicinal products.

The company says the drug was approved in the United States on 26 August 2026 with a broader label, which also covers patients who are not candidates for multiagent treatment. Outside the US it is investigational until a regulator decides.

The survival numbers behind the Rasonque EMA recommendation

Two overall-survival figures circulate, so it is worth being precise. In the prespecified main analysis of the RASolute 302 trial, median overall survival was 13.2 months with Rasonque and 6.7 months with the investigator’s choice of chemotherapy, a hazard ratio of 0.40, meaning a 60% lower risk of death over the period studied. The 12.4 months versus 6.7 months figure comes from a later ad hoc analysis, with a hazard ratio of 0.49. Sources differ on whether that analysis covered the whole trial population or the RAS G12 mutant group, so we quote both and describe the second as ad hoc. Either way, the survival gap is large.

Median progression-free survival, the time before the disease grew or the patient died, was 7.2 months with Rasonque and 3.6 months with chemotherapy (hazard ratio 0.49). Reports of the published trial add that about 53% of patients on Rasonque were alive at 12 months versus about 17% on chemotherapy, and that confirmed tumour shrinkage occurred in about 32% versus 11%.

Who was studied in RASolute 302

RASolute 302 was a global, randomised Phase 3 trial in previously treated metastatic pancreatic cancer. It enrolled 500 patients, according to reports of the published results, who received Rasonque or one of several chemotherapy regimens chosen by their doctor. The company says the trial met its primary and key secondary endpoints in both patients with a RAS G12 mutation and the overall population, with or without an identified RAS mutation. The main analysis was presented at the 2026 ASCO meeting and published in the New England Journal of Medicine.

Side effects behind the Rasonque EMA recommendation

The company lists the most common adverse reactions as diarrhoea (63.1%), acneiform dermatitis (62.4%), stomatitis or mouth sores (55.5%), nausea (50.8%), vomiting (41.6%) and fatigue (33.2%). In the US label, serious adverse reactions occurred in 30% of patients, and 2.9% stopped treatment permanently because of side effects. Gastrointestinal perforation (0.9%) and lung inflammation known as interstitial lung disease or pneumonitis (2.4%) each included one fatal case. The label also warns about harm to an unborn baby and advises contraception. Skin care, sun protection and sometimes antibiotics are recommended to manage rash.

What the Rasonque EMA recommendation means for patients

For now, nothing changes for patients in Europe. The European Commission still has to decide, and after any authorisation, national pricing and reimbursement decisions usually determine when a medicine actually reaches patients in each country. The company’s figures say about 147,000 people are diagnosed with pancreatic cancer in Europe each year, with five-year survival below 10% and about 80% diagnosed after the disease has spread. Those figures are the company’s and are not independently checked here. A doctor can advise whether any treatment suits an individual patient.

Risks and caveats for the Rasonque EMA recommendation

• This is a committee opinion. The European Commission’s decision is still pending.
• Rasonque is not a cure. Median survival improved by months, not years, in the trial.
• The trial was open-label, and patients had varied chemotherapy comparators.
• Side effects are common and can be serious. The label carries several warnings.
• Some trial details come from reports of the published paper, which we could not read directly. Standard forward-looking risks apply to company statements.

In our assessment, the survival gain behind the Rasonque EMA recommendation, in a hard-to-treat cancer, is large enough to explain the regulatory speed, but the benefit has to be weighed against frequent side effects and the lack of a cure. For related oncology coverage, see our report on an early breast cancer trial and more in pharmaceutical news.

What to watch next for the Rasonque EMA recommendation

• The European Commission’s decision and any final EU wording of the indication.
• National pricing and reimbursement decisions.
• Results of RASolute 303, which tests the drug as a first-line treatment.
• Longer follow-up on survival and safety.

Questions about the Rasonque EMA recommendation

Is Rasonque approved in Europe?

Not yet. The CHMP recommended authorisation on 15 October 2026. The European Commission makes the final decision.

What is Rasonque used for?

The proposed use is in adults with metastatic pancreatic adenocarcinoma who have had at least one prior systemic therapy.

How much longer did patients live?

Median overall survival was 13.2 versus 6.7 months in the main analysis, and 12.4 versus 6.7 months in an ad hoc analysis.

Is Rasonque a cure?

No. It extended survival in the trial, but it does not cure the disease.

How we reported this: we relied on Revolution Medicines’ announcement of 15 October 2026 and its description of the trial, with additional trial details from reports of the published results. Percentages quoted for side effects are the company’s. Last updated: 16 October 2026. This article is news reporting and not medical advice.